NOVARTIND · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 40/100 — Quality 67 · Valuation 1
| Share price | ₹1,667.90 |
| Market cap | ₹3,690 Cr |
| P/E ratio | 39.5 |
| P/B ratio | 4.5 |
| ROCE | 15.7% |
| Book value | ₹331.34 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹354 Cr | ₹93 Cr | 26.0% |
| 2025 | ₹356 Cr | ₹101 Cr | 26.5% |
| 2024 | ₹334 Cr | ₹85 Cr | 19.5% |
| 2023 | ₹369 Cr | ₹103 Cr | 18.8% |
| 2022 | — | — | — |
Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited operates as a subsidiary of Novartis AG.